The quail Pax-6 gene is expressed from two promoters named P0 and P1. P0 promoter is under the control of a neuroretina-speci®c enhancer (EP). This enhancer activates the P0 promoter speci®cally in neuroretina cells and in a developmental stage-dependent manner. The EP enhancer binds eciently, as revealed by southwestern experiments, to a 110 kDa protein present in neuroretina cells but not in Quail Embryos Cells and Retinal Pigmented Epithelium which do not express the P0-initiated mRNAs. To study the role of p110 in Pax-6 regulation, we have puri®ed the p110 from neuroretina cells extracts. Based on the peptide sequence of the puri®ed protein, we have identi®ed the p110 as the poly(ADP-ribose) polymerase (PARP). Using bandshift experiments and footprinting studies, we present evidence that PARP is a component of protein complexes bound to the EP enhancer that increases the on rate of the protein complex formation to DNA. Using PARP inhibitors (3AB and 6.5 Hphe), we show that these products are able to inhibit EP enhancer activity in neuroretina cells. Finally, we demonstrate that these inhibitors are able to decrease the expression of the P0-initiated mRNA in the MC29-infected RPE cells which, in contrast to the RPE cells, accumulated the PARP in response to v-myc expression. Our results suggest that PARP is involved in the Pax-6 regulation.
Introduction
The Pax gene family, which contains nine members in vertebrates, encodes phylogenetically conserved transcription factors that play an important role in embryonic development (for reviews see Dahl et al., 1997) . Some of these genes (Pax-3, Pax-4, Pax-6 and Pax-7) bear two DNA-binding domains, namely paired and homeodomains, the others bearing the paired domain alone (Pax-1, Pax-2, Pax-5, Pax-8 and Pax-9) (for review see Mansouri et al., 1996) . Pax genes can be considered proto-oncogenes, as their overexpression results in transformation of rat ®broblasts (Maulbecker and Gruss, 1993) . Moreover, PAX-3 and PAX-7 are involved in chromosomal translocation consistently found in alveolar rhabdomyosarcoma (Galili et al., 1993; Davis et al., 1994) .
In vertebrates, the Pax-6 gene is expressed in the developing central nervous system, the optic cup, lens and overlaying epithelium prior to morphological dierentiation, and later in the neural layers of the retina (for a review see Callaerts et al., 1997) . In addition, Pax-6 is also expressed in the endocrine pancreas (Turque et al., 1994) . Analysis of naturally occurring mutations in Pax-6 demonstrates a key role of this gene in eye development. Indeed Pax-6 mutations in mice (small eye) (Hill et al., 1991) and rats (Fujiwara et al., 1994) result in a lack of eyes in homozygotes and reduced eye size in conjunction with lens and iris defects in heterozygotes. In human the PAX-6 gene has been found deleted or mutated in many cases of the disorders aniridia and Peters anomaly which lead to a variety of visual defects associated with the iris and anterior chamber (for review see Prosser and van Heyningen, 1998) . Moreover, this gene is the homologue of the eyeless gene of Drosophila, which is also involved in eye morphogenesis (Quiring et al., 1994) and targeted expression of Pax-6 or eyeless in Drosophila imaginal discs results in the formation of ectopic eyes (Halder et al., 1995; Glardon et al., 1997; Tomarev et al., 1997) , placing this gene as a master regulator of eye development.
Our research focuses on the regulatory elements involved in the eye-speci®c expression of the Pax-6 gene. We have previously shown that Pax-6 expression in the quail neuroretina is regulated via two promoters, P0 and P1, P0 being activated at the onset of neuronal dierentiation (Plaza et al., , 1995b . We have identi®ed an intragenic neuroretina-speci®c enhancer (EP enhancer) whose activity is restricted to the P0 promoter and functions in a developmental stagedependent manner in embryonic neuroretina, paralleling the level of P0-initiated mRNAs expression (Plaza et al., 1995a) . This enhancer element contains four neuroretina-speci®c nuclear proteins binding sites (named DF1, DF2, DF3 and DF4), involving a common set of proteins with a major 110 kDa protein strongly detected in neuroretina cells (Plaza et al., 1995a) .
In the present study, we have puri®ed the 110 kDa from neuroretina cells nuclear extracts and identi®ed this protein as the poly(ADP-ribose) polymerase (PARP). PARP is a nuclear chromatin associated enzyme that catalyses the transfer of ADP-ribose derived from NAD + to nuclear protein acceptors, including mainly the enzyme itself, topoisomerase I and II, histones, and HMG proteins . The PARP protein contains three functional domains: a DNA binding domain located at the amino terminus, a central automodi®cation domain that acts as an acceptor for poly(ADP-ribose) and a catalytic domain at the carboxyl terminus (de Murcia et al., 1991; de Murcia and MeÂ nissier de Murcia, 1994 , Lindahl et al., 1995 . The PARP activity is strongly stimulated by the presence of nicks and strand breaks in DNA. These observations have contributed to the idea that PARP mediates stress induced signalling and functions in a NAD-dependant manner in certain DNA repair processes (Lindahl et al., 1995; Chatterjee and Berger, 1994; Stevnsner et al., 1994) . Automodi®cation releases PARP from DNA, thus providing a mechanism that renders the DNA more accessible to the DNA repair machinery . In the absence of NAD, PARP inhibits DNA repair through binding to damaged DNA . Other functions proposed for PARP include roles in cellular NAD depletion (Berger, 1985) , antirecombination and genomic stability , and DNA replication (Simbulan-Rosenthal et al., 1996) . PARP also serves as marker for the onset of apoptosis, after which it is cleaved by proteases into DNAbinding and catalytic fragments (Tewari et al., 1995) . Finally, recent studies suggest that PARP may play a role in gene regulation. Indeed, Roeder and co-workers puri®ed PARP as a co-factor of RNA polII mediated transcription and other authors have shown the ability of PARP to interact with sequence-speci®c transcription factors (Dear et al., 1997; Meisterernst et al., 1997; Nie et al., 1998; Vaziri et al., 1997) .
Here we show that PARP is a component of the protein complexes bound to the DF4 protein-binding site of the Pax-6 neuroretina-speci®c enhancer and could increase the on rate of the protein complexes formation to DNA. Using known PARP inhibitors, we show that they are able to inhibit enhancer-mediated transactivation in neuroretina cells. In addition, we demonstrate that, whereas the PARP is not present in the P0-non expressing Retinal Pigmented Epithelium cells (RPE), expression of v-myc in these cells both induced PARP and P0 mRNA expression. The PARP inhibitors are also able to inhibit P0 mRNA expression in these cells suggesting a role for PARP in the Pax-6 gene regulation into the neuroretina.
Results

Puri®cation and identi®cation of the p110 from neuroretina cells
We previously identi®ed in E8 neuroretina cells a 110 kDa nuclear protein which binds to the four protein binding sites (DF1, DF2, DF3 and DF4) identi®ed within the Pax-6 neuroretina-speci®c enhancer (EP enhancer) (Plaza et al., 1995a) . To purify and identify this 110 kDa protein, nuclear extracts prepared from 1600 neuroretinas were passaged through several cycle of Heparin-sepharose column and DNA-anity column. As previously described and in contrast to the other binding sites identi®ed within the EP enhancer, multimerization of the DF4 site mimics the enhancer activity (Plaza et al., 1995a) indicating that in this context, the DF4 protein binding site is able to bind all the proteins necessary to mediate enhancer activity in neuroretina cells. Thus, the DNA-anity column was prepared using multimerized DF4 oligomers immobilised on NHS sepharose beads The puri®cation of the 110 kDa protein (p110) was monitored by southwestern experiments using the DF4 protein binding site as probe and DNaseI footprinting analysis.
Heparin chromatography The neuroretina nuclear extracts (50 mg) were ®rst applied onto a Heparin column at 0.112 M KCl. In these conditions, only 10% of the proteins present in nuclear extracts were retained on the column (Figure 1b , compare lanes QNR and FTH,¯ow through). After elution using a linear gradient of KCl ( Figure 1a ) the elute material was monitored for the presence of the 110 kDa protein (p110) by Southwestern experiments. As shown in Figure 1c , among the proteins bound to the Heparin column we detected the p110 in the fractions eluted between 0.25 ± 0.4 M KCl, whereas no p110 could be detected in the FTH fraction. Moreover, p110 was also detected directly by silver staining (Figure 1b) . In order to determine whether the p110 containing fractions were able to speci®cally bind the enhancer, the eluted fractions were tested by DNaseI footprinting. The FTH proteins showed no footprint on the EP enhancer indicating that the proteins of interest were retained onto the Heparin column (data not shown). As shown in Figure 1d , only the eluted p110-containing fractions (lanes H27 and H32) were able to give a DNaseI footprint and hypersensitive sites on the EP enhancer reminiscent of those obtained with neuroretina nuclear extracts ( Figure 1d , lane QNR).
Anity chromatography In order to purify the p110, we next applied the p110-containing Heparin fractions (H25 to H33) onto a DF4 anity column at 50 mM KCl. After elution using a linear gradient of KCl (Figure 2a) , the eluted proteins (0.2 ± 0.4 M KCl) were silver stained. As shown in Figure 2b the material eluted at high KCl concentration (lane AF2) contained only a puri®ed p110 protein whereas this protein copuri®ed with other proteins (MM 60, 50 and 27 kDa) in the material eluted at lower KCl concentration (lane AF1). Southwestern blot experiments performed with fractions AF1 or AF2 con®rmed that the p110 recovered shares the DNA binding activity detected in neuroretina cells extracts ( Figure  2c ). When DNaseI footprinting assays were performed with these fractions, the AF1 fraction ( Figure 2d , lane AF1) gave a footprint and hypersensitive sites on the EP enhancer reminiscent of those obtained with neuroretina nuclear extracts ( Figure 2d , lane QNR) whereas the AF2 fraction did not ( Figure 2d , lane AF2). These results show that the p110 (fraction AF2) is not able alone to protect the EP enhancer. However the ability of fraction AF1 to footprint the EP enhancer strongly suggests that p110 is one component of a multiprotein complex which speci®cally binds to this enhancer. Four peptide sequences obtained from the puri®ed 110 kDa protein exhibit 100% identity with human and chicken Poly(ADP-ribose)polymerase (PARP) (Ittel et al., 1991) and identify the p110 as PARP.
Involvement of PARP in the protein-DF4 complexes formation
In order to con®rm the involvement of PARP in the protein complexes present on the DF4 protein binding site, bandshift experiments were performed using DF4 as probe together with E8 neuroretina nuclear extracts and antibodies directed against PARP (A318). As shown in Figure 3a , addition of PARP antibodies after incubation of neuroretina nuclear extracts with the probe resulted in supershift complexes (lane NE+A318 post as compared with lane NE) whereas the PARP antibodies alone did not bind to the probe (lane A318). Interestingly, preincubation of PARP antibodies with neuroretina nuclear extracts before adding the probe partially blocked protein complexes formation on the DF4 probe (lane NE+A318pre compare to lane NE). No variation in complexes formation was observed with a non immune serum (lane NE+NI). The inhibition of complex formation was speci®c since the PARP antibodies did not aect the binding of the Pax-6 paired DNA-binding domain on its consensus sequence ( Figure 3b , lane PAIRED+A318). Moreover, no inhibition for complex formation of USF or SP1 transcription factors present in Neuroretina nuclear extracts to their respective consensus sequence could be observed (not shown) using PARP antibodies. Therefore, PARP is not randomly present in every DNA-protein complexes. These results suggest that PARP is present within the protein complexes bound to the DF4 probe.
The anity of a protein for its ligand is function of rates of association and dissociation. In order to address the role of PARP in protein complexes bound to the DF4 probe we analysed by bandshift experiments the eects of PARP depletion on both the dissociation and association rates of protein-DF4 complexes in neuroretina nuclear extracts. PARP was removed from the nuclear extracts using antibodies linked to sepharose beads according to the material and methods. We have used a large excess of antibodies per mg of nuclear extracts to ensure total PARP depletion.
To study the dissociation rate, neuroretina nuclear extracts depleted or not of PARP were incubated for 1 h with labelled DF4 probe to form the DNA-protein complexes. After initial binding, a 100-fold excess of the unlabelled DF4 oligonucleotide was added to the reaction and aliquots were withdrawn at various time points and immediately loaded onto gels. The decrease in the intensity of the protein/DNA band shown in panel A re¯ects the dissociation rate of the complex. The intensity of the binding complex from each aliquot was plotted as the percent of complexes remaining in the reaction versus reaction time (assuming the amount of complexes at time 0 is 100%). As shown in Figure  3c , the curves with or without PARP are superimposable, suggesting that the dissociation rate of DF4-Proteins complexes is the same under both circumstances and therefore that PARP is not implicated in the dissociation of the complexes.
To study the association rate, neuroretina nuclear extracts depleted or not of PARP were mixed with the DF4 probe and aliquots were removed at various time points and analysed by gel electrophoresis. Figure 3d shows that the association is extremely rapid. When the intensities of the complex band were plotted versus the time of interaction, the faster on-rate of PARP+ neuroretina extract than PARP7 neuroretina extracts during the ®rst min of interaction was evident (the PARP containing nuclear extracts associates to DF4 twofold more rapidly than the PARP depleted nuclear extracts). At higher time of incubation, this dierence decreases (only 20% dierence could be detected between the two extracts). These results suggest that PARP is implicated in the binding of the protein complexes present on DF4 by increasing its association rate without altering the stability of the protein-DNA complexes.
In order to strengthen this observation, we have performed reconstitution experiments using a bacterially expressed puri®ed His tagged PARP encompassing the automodi®cation domain (referred as PARS/ AMD, Nie et al., 1998) . Bandshift experiments using increasing amount of PARS/AMD and neuroretina nuclear extracts depleted or not were performed using DF4 probe and UE probe as control (Figure 3e ). When the His tagged PARS/AMD was added to the nuclear extracts, a prominent retarded complex was observed. Identical results are obtained using the PARP depleted nuclear extracts, indicating that PARP depletion procedure did not remove, through protein/protein interaction, the other proteins able to bind the DF4 probe. The dierences in the faster migrating complex observed can be due to the reduced size of PARP used instead the full length PARP. To con®rm whether this retarded complex was due to the binding of PARS/ AMD, we added PARP antibodies to the reaction mixture. A supershift is observed (arrowhead in Figure  3e ) and con®rm the presence of PARS/AMD in this on the association and dissociation rate of the complexes. E8 neuroretina nuclear extracts were incubated with non immune serum (*) or PARP antibodies A318 (&). (c) Dissociation rates of the protein-DNA complexes. One mg of neuroretina nuclear extracts were incubated with radiolabelled DF4 oligonucleotide for 1 h at room temperature. After loading the ®rst aliquot on a gel, a 100-fold molar excess of unlabelled speci®c oligonucleotide was added and the reaction mixture was further incubated for the indicated times. The protein-DNA complexes were quanti®ed with a Phosphor Imager and expressed relative to the ®rst aliquot. (d) Association rates of the protein-DNA complexes. One mg of QNR nuclear proteins were incubated with radiolabelled DF4 oligonucleotide for the various times indicated at the bottom of the ®gure at room temperature and loaded onto the gel. The protein-DNA complexes were quanti®ed with a Phosphor Imager. (e) Eect of recombinant PARP protein (PARS/AMD) for complex formation on the DF4 probe. Increasing amount indicated (ng) of recombinant PARP protein is mixed with neuroretina nuclear extracts (1 mg) and the indicated probe. Antibodies (1 ml) were added in the reaction mixture. Only the complex is shown retarded complex. The same amount of non immune antibody did not aect the complex (not shown). The PARS/AMD protein (devoid of the DNA binding domain) did not interact alone with the probe. Moreover, no additional complex formation was formed with PARS/AMD on the UE probe using neuroretina nuclear extracts (Figure 3e ). Altogether these results demonstrates the involvement of PARP in the protein complex formation on the DF4 probe.
Involvement of PARP in Pax-6 enhancer mediated transactivation
Since PARP is present in the complexes formed on the DF4 binding site, we investigated its involvement in neuroretina-speci®c enhancer activity. To address this question, CAT reporter plasmids carrying the EP enhancer (tkEP) or three copies of the DF4 site downstream the CAT gene (tkDF4) were transiently transfected in E8 neuroretina cells (QNR) in presence of PARP inhibitors, and assayed for CAT activity. When the PARP inhibitor 3 aminobenzamide (3AB) was used, a 60% inhibition in enhancer activity of the tkEP and tkDF4 constructs was observed (Figure 4a and b) . No inhibition of CAT activity was observed either on the tk promoter (Figure 4a ) or on a stronger one, the chicken c-mil and SV40 promoters (data not shown), or on a tkDF4 construct mutated in the DF4 site (tkDF4mt5) and devoid of enhancer activity (Figure 4a and b) . Similar results were obtained when an other PARP inhibitor 6.5 Hphenantridinone (6.5 Hphe) was used. However, the CAT activity of the construct tkEP was not reduced by the PARP inhibitors in quail embryo cells (QEC) (Figure 4c ) in which the EP enhancer has no activity and that contains low level of PARP in the nucleus (Plaza et al., 1995a and Figure 5) . Altogether, these results indicate that the inhibition of EP enhancer activity in QNR is not a consequence of basal transcriptional machinery inhibition via the promoter but is rather speci®c of the enhancer function. Since 3AB and 6.5 Hphe are competitive inhibitors of poly ADPribosylation, our results also suggest that poly ADPribosylation reaction by PARP is involved in the EP enhancer activity in neuroretina cells.
To investigate the role of poly ADP-ribosylation in neuroretina cells, in vitro ADP-ribosylation experiments were performed using [adenylate-a-32 P]NAD as the ADP-ribose donor, and crude or puri®ed nuclear neuroretina extracts and the results were visualised after electrophoresis in denaturing conditions. As shown in Figure 4d , only three bands could be detected in crude nuclear neuroretina extracts, corresponding to PARP and Poly ADP-ribosylated PARP molecules. This signal is inhibited by 3AB con®rming that this inhibitor is indeed active. No other labelled proteins could be detected in nuclear extracts neither in anity puri®ed fractions (not shown), indicating that PARP is the major substrate for ADP ribosylation in neuroretina cells. This suggests that the inhibition of EP enhancer activity observed in QNR with PARP inhibitors is due to the lack of PARP ADP ribosylation.
Western blot and Southwestern blot experiments revealed that QEC (and RPE) cells expressed only a low level of PARP protein in the nucleus whereas mRNA are clearly detectable in all these cells (Figure 5a ± c and Plaza et al., 1995a) . QEC (and RPE) cells are not able to support the EP enhancer activity on the P0 promoter of Pax-6 (Plaza et al., 1995a) . In order to con®rm the involvement of PARP in EP enhancer activity, we performed co-transfection experiments in these cells using PARP expression vectors and Pax-6 promoter CAT constructs carrying or not the EP enhancer downstream the CAT gene (P0EP and P1EP) . The Pax-6 P0 promoter is activated by the EP enhancer in neuroretina cells, in contrast to the Pax-6 P1 promoter (Plaza et al., 1995b) . As shown in Figure 5d , PARP was able to increase the CAT activity of the P0EP construct whereas P1EP construct was insensitive to PARP activation. These results show that the Pax-6 P0 promoter, activated by the EP enhancer in neuroretina cells, is also sensitive to PARP All these results suggest that PARP is one of the factors involved in the regulation of the EP enhancer in neuroretina cells.
Involvement of PARP in Pax-6 expression
We have previously shown that retinal pigmented epithelial cells (RPE) expressed Pax-6 only from the P1 promoter (Plaza et al., 1995b) . Nuclear extracts prepared from these cells expressed very low level of PARP (Figure 5b , c) and were unable to footprint this enhancer (Plaza et al., 1995a) . After infection of RPE with the retrovirus MC29 carrying the v-myc oncogene, these MC29-RPE cells exhibit neuronal traits in culture and expressed Pax-6 from the P0 and P1 promoters (Plaza et al., 1995b) . Since the P0 promoter is activated by the EP enhancer, we have tested the nuclear extracts from MC29-RPE cells for the binding of PARP on the EP enhancer and for their ability to footprint the EP enhancer. Southwestern experiments revealed ( Figure  6a ) that nuclear extracts from MC29-RPE exhibit high binding of PARP to the EP enhancer, similarly to QNR, and in contrast to RPE (Plaza et al., 1995a and Figure 5c ) or RPE-NR5 which carry the mil/raf oncogene (Figure 6a ). DNaseI footprinting experiments show that the four protected regions revealed with QNR nuclear extracts were also observed with the MC29-RPE nuclear extracts (Figure 6b ), in contrast to the RPE nuclear extracts (Plaza et al., 1995a) . Moreover, the pattern of DNaseI digestion (footprint and hypersensitive sites) observed with the MC29-RPE nuclear extracts was identical of the one obtained with QNR nuclear extracts (Figure 6b ), suggesting that all the proteins needed to activate the EP enhancer were present in MC29-RPE cells.
To test the possibility that PARP was able to regulate the P0 promoter (through the EP enhancer) in vivo, MC29-RPE cells were passaged in the absence or in the presence of PARP inhibitor 3AB in the culture medium. The cells were harvested after one week of culture, RNAs were extracted and RNase protection experiments were performed in order to measure the levels of P0-and, as control, P1-initiated mRNAs. Figure 6c shows in two independent experiments that cells cultured in the presence of PARP inhibitor 3AB expressed lower level of P0-initiated mRNAs whereas the P1-initiated mRNAs remained constant.
Nuclear extracts were prepared from these cells cultured in the presence of PARP inhibitor in order to study complex formation to the DF4 probe. Figure 6d revealed, using untreated RPE MC29 nuclear extracts, a complex on the DF4 probe exhibiting the same slow migrating complex than obtained using neuroretina nuclear extracts. This complex formation, in agreement with the results obtained using neuroretina nuclear extracts, is speci®cally inhibited when PARP antibodies Southwestern analysis performed using the DF4 oligonucleotide as probe. At higher exposure time, very low signal of PARP binding could be detected in QEC and RPE nuclear extracts. The same transferred membrane was ®rst used in Southwestern blot experiment and, after exposure, treated with PARP antibodies. Similar results were obtained after mesurement of poly(ADPribose) activity between these dierent cells (not shown). (d) cotransfection experiments performed in QEC using PARP expression vectors and Pax-6 promoter CAT constructs (P0EP, P1EP) carrying the EP enhancer downstream the CAT gene. One mg of promoter construct and 0.25 mg of PARP expression vector pECV PARP (a generous gift of G. de Murcia) were cotransfected into QEC using lipofectamine reagent (GIBCO ± BRL). In some experiments 0.5 mg of plasmid SV40Luc was cotransfected with the CAT constructs as an internal control of transfection eciency. The total amount of DNA is kept constant by addition of the vector control. The CAT activities of the CAT constructs in the absence of the PARP expression vector were arbitrarily set at a value of 1. The results presented are the average of three independent experiments with the standard deviations indicated by error bars are added before the probe. These antibodies did not modify the binding of the nuclear extracts on the UE probe. Thus in RPE MC29 nuclear extracts, PARP is also involved in the protein/DNA complex formation on the DF4 probe. Moreover, the nuclear extracts prepared from 3AB RPE MC29 cultured cells revealed a reduced binding capacity to the DF4 probe when compare to the control (RPE MC29). This reduced binding capacity is well correlated with the diminution of P0 mRNA expression.
All of these results show a correlation between PARP binding ability on the EP enhancer and Pax-6 mRNA expression from the P0 promoter, suggesting a role of PARP proteins in the Pax-6 gene regulation.
Discussion
We have previously identi®ed within the Pax-6 gene a developmentally-regulated neuroretina-speci®c enhancer (EP) whose activity is restricted to the Pax-6 P0 promoter (Plaza et al., 1995a) . This enhancer is unable to enhance Pax-6 P0 promoter activity in P0-initiated mRNAs non-expressing cells (QEC and RPE). Southwestern blot experiments using the enhancer sequence as probe have revealed, in neuroretina cell extracts, a protein of 110 kDa not detected in QEC and RPE cell extracts, suggesting a role for this protein in the regulation of the EP enhancer activity (Plaza et al., 1995a) . In the present study, we have puri®ed this 110 kDa protein (p110) from neuroretina cells extracts and identi®ed it as the poly(ADP-ribose) polymerase (PARP). During puri®cation, we found a good correlation between the presence of PARP in the puri®ed fractions and the ability of these PARPcontaining fractions to footprint the EP enhancer. Previous study using bandshift and Southwestern blot experiments suggested that similar factors bind to the four protein binding sites identi®ed within the EP enhancer (DF sites). Fractions puri®ed on DF4-anity column are able to protect the DF1, DF2 and DF3 sites within the enhancer. This con®rms that, despite the dierences in their sequences, the four DF sites bind the same protein complexes.
Although PARP alone shows a DNA binding activity on the EP enhancer, it is not able to footprint this enhancer and additional proteins are necessary to obtain a full-footprint of the EP enhancer. This is reminiscent of other studies showing PARP as a nonspeci®c DNA binding protein which binds to a V shaped conformation induced by single strand breaks, crossovers and to cruciforms DNA (de Murcia et al., 1991, de Murcia and Menissier-de Murcia 1994; Sastry and Kun, 1990 ). Thus it is quite possible that PARP binds the EP enhancer sequences through a peculiar conformation of this enhancer. Gaillard and Strauss (1994) showed that cruciform structure formations are dependent on poly(CA).poly(TG) dinucleotide. The presence of (i) 26 CA/TG within the 216 bp enhancer sequence and (ii) some stretches of sequence homologies between the DF site (Plaza et al., 1995a) suggest that secondary structures may be formed in the EP enhancer.
Although we can not exclude that PARP was puri®ed in our experiments through its non speci®c DNA binding activity, puri®cation experiments using Figure 6 Involvement of PARP on Pax-6 expression in MC29-infected RPE cells. (a) Southwestern blot analysis of MC29-infected RPE nuclear extracts (100 mg) using the DF4 oligonucleotide as a probe. NR5 RPE cells are RPE cells infected with the retrovirus NR5 carrying the mil/raf oncogene. (b) DNaseI footprinting analysis of the EP enhancer using MC29-infected RPE nuclear extracts (100 mg). Boxes marked the position of the footprints (DF1 to DF4) and asterisks show hypersensitive sites. (c) RNase protection analysis of mRNAs extracted from MC29-infected RPE cells cultured in the absence (CONTROL) or presence of 3 aminobenzamide 10 mM (3AB) for a week. Two independent experiments are presented. The level of P07 versus P17 initiated mRNAS was quanti®ed using a Phosphor Imager. (d) Binding of nuclear extracts from RPE MC29 cells cultured in the absence and the presence of 3AB. The probe used is indicated on the top. PARP antibodies (A318) are preincubated with the nuclear extracts. Only the retardated complexes are shown tandem anity-chromatography columns with a mutant DF4 oligonucleotide (devoid of enhancer activity) on the ®rst column and wild type oligonucleotide on the second column argues against this hypothesis. Indeed, only low level of PARP is retained on the mutant DF4-anity column whereas high amount of PARP is retained together with additional proteins on the wild type anity chromatography (data not shown). This observation raises the possibility that PARP is part of a protein complex and is retained in part onto the column through protein-protein interactions. In this respect, we have shown by bandshift assays that PARP is present in the DNA-protein complexes bound to the DF4 site. One can speculate a physical interaction between PARP and speci®c transcription factors bound to this sequence. The binding of the automodi®cation domain of PARP alone to DF4 in the presence of nuclear extracts strenghtens this hypothesis. Interestingly, recent studies described protein interactions between PARP and transcription factors such as E47, p53, YY1 and Oct1 (Dear et al., 1997; Vaziri et al., 1997; Nie et al., 1998) . Our studies, using PARP depleted nuclear extracts and His tagged recombinant PARP protein, suggest that PARP increases the on rate of proteins binding to DNA. Similar results were previously obtained in reconstitution experiments using bacterially PARP and Oct1 proteins (Nie et al., 1998) . Indeed the interactions between the automodi®cation domain of PARP and Oct1 increase the anity of Oct1 for the octamer motif of the DRa promoter.
Alternatively, PARP could interact with a coactivator increasing the eciency of the transcriptional machinery bound to the EP enhancer. Of interest, one of the proteins isolated on the column is the ALY coactivator as shown by protein sequencing of the p27 protein. ALY, a non DNA binding protein, has been recently found to increase the binding anity of AML-1 and LEF-1 on the TCRa enhancer (Bruhn et al., 1997) . Additional works is needed to study the protein interaction between PARP and ALY.
It should be noted that the automodi®cation domain of PARP, which participate for complex formation to DF4, encompasses a BRCT (BRCA1 C terminus) module that is an interface for protein-protein interaction (Bork et al., 1997; Callebaut and Mornon, 1997) . Interestingly, the carboxyterminal BRCT domain of BRCA1, a tumor suppressor speci®c for breast and ovarian cancers, corresponds precisely to the minimal transcription activation domain of this protein (Bork et al., 1997; Callebaut and Mornon, 1997 ). It appears likely that this activation is mediated by the interaction between the BRCT domains and RNA polymerase or transcription factors.
The role of PARP in enhancer activity was demonstrated using PARP inhibitors in transient transfection experiments. These inhibitors decrease the enhancer activity in neuroretina cells, suggesting that ADP-ribosylation is important for EP enhancer activity. The mechanism by which PARP acts remains unknown but dierent hypothesis could be discussed. First, PARP is able to ADP-ribosylate the speci®c transcription factors bound to the enhancer, in order to modulate their DNA binding or transcriptional activity. Interestingly, p53 is a substrate for PARP in vitro and in vivo (Wesierska et al., 1996) . Unfortunately, we were unable to detect ADP-ribosylation of proteins in neuroretina nuclear extracts or in anitypuri®ed proteins other than PARP itself. Second, PARP could be in fact an inhibitor on the EP enhancer activity in the neuroretina and ADPribosylation of PARP itself would release PARP from DNA. In this case, inhibition of ADP-ribosylation would block the PARP to the EP enhancer and consequently modify the protein/DNA topology and thus inhibit enhancer activity. Third, since histones are known as substrate of PARP, branched ADP-ribose polymers or ribosylation of chromatin-associated proteins may also lead to changes in chromatin conformation and may thereby serve to control enhancer activity. Fourth, ADP ribose polymers synthetized by PARP interact with the factors regulating the EP enhancer. Interestingly, Malanga et al. (1998) recently described interaction between ADPribose polymers and p53 that modulate its DNA binding activity.
An important question which remains to be addressed, is whether PARP regulates the Pax-6 P0 promoter in vivo. MC29-infected RPE cells, in contrast to the normal RPE cells, expressed Pax-6 from the P0 promoter (Plaza et al., 1995b) . These cells, in contrast to RPE, exhibit high amount of PARP in the nucleus. MC29-RPE cells show a reduced level of P0-initiated mRNAs when cultured in the presence of PARP inhibitor 3AB, whereas the P1-initiated mRNAs remained constant. This result suggests that PARP participates in vivo to the regulation of the Pax-6 P0 promoter. Mice de®cient in PARP activity were born healthy and fertile indicating that PARP plays no essential role in cellular proliferation, dierentiation or development (Wang et al., 1995) . Moreover no obvious abnormalities in the Pax-6-expressing tissues (i.e. neural tube, brain, eye and pancreas) have been reported. However only the Pax-6 P0 promoter could be aected in its regulation after PARP disruption which might result in the eye in a subtile phenotype preserving the overall structure and thus not easily detectable. A more extensive examination of the eyes in mice PARP 7/7 should be undertaken.
Our results strongly suggest a link between PARP and the Pax-6 gene regulation. PARP might be a cofactor within the protein complex bound to the EP enhancer, associated with sequence-speci®c transcription factors which remain to be identi®ed.
Materials and methods
Oligonucleotides
The following set of synthetic oligonucleotides was used (all sequences are written 5' to 3'): DF4F, GATCC-GGGGCGACTTCCGCCTATTTCCA GAAATTAAGCT-CAAAC TTGACGTGCAGCTA; DF4R, gatCTAGCTG-AAGTTTGAGCTTAATTTCTGGAAATAGGCGGAAG-TCGCCCCG. The underlined sequence are 5'-overhanging ends compatible with BamHI or BglII restriction sites. 5, CCAGAAATTACTAGAAAACTTGACGTG. In bold letters are the mutated nucleotides. 28S, GGAATCCTGGT-TAGTTTCTTTTCCTCCGCT. UE sequence derived from Moncollin et al. (1990) , GGTGTAGGCCACGTGAC CGGGTGT and its complementary strand ACACCCGGT-CACGTGGCCTACACC.
Plasmids
Plasmids pTKCAT (tk in text), pTKCAT EP (tKEP), pTKCAT 3xDF4 (tkDF4), pP0CAT EP (P0EP) and pP1CAT EP (P1EP) were described previously (Plaza et al., 1995a) . Mutations in the DF4 site were made on a 188 bp EcoRI ± SmaI fragment containing three copies of the 58-bp DF4 site inserted in the M13mp18 vector. The single stranded directed mutagenesis was conducted with an Amersham oligonucleotide-directed in vitro mutagenesis system using the oligonucleotide 5 described above. Mutations on the three copies of the DF4 site were con®rmed by nucleotide sequence analysis. The mutated DF4 CAT plasmid (tkDF4mt5) was constructed by cloning the mutated 3xDF4 fragment, excised from the M13mp18 vector, into the SacI ± SmaI sites of pTKCAT.
Nuclear protein preparation
Nuclear extracts were prepared from quail embryonic day 8 (E8) neuroretina (QNR) or retinal pigment epithelial cells (RPE) and 10-day-old quail embryo cells (QEC) as described previously (Plaza et al., 1995a) . Protein concentrations were determined with the Bradford method (BioRad).
Puri®cation of p110
For the molecular studies, QNR nuclear extracts were prepared from 160 E8 dissected embryos. For sequencing of p110, 1600 neuroretinas were used. Nuclear extracts were dialysed against buer A (10 mM Tris-HCl pH 8, 112 mM KCl, 5% (V/V) glycerol, 4 mM HEPES pH 7.9, 0.2 mM EDTA, 0.025 mM EGTA, 1 mM dithiotreitol (DTT) 1 mM PMSF) over-night. The puri®cation was performed using a biologic workstation (BioRad). The nuclear extracts were applied onto an econo-pac Heparin cartridge (BioRad) equilibrated with buer A. The¯ow through (FTH) was collected and the column was washed (2 ml/min) with 10 column volumes of buer A. Bound proteins were eluted using KCl gradient (0.112 to 1 M) in the same buer. Fractions of 1 ml were collected (¯ow rate 2 ml/min). The Heparin fractions, containing the p110 and footprint activity were pooled and diluted with buer A without KCl to give a ®nal concentration of 50 mM KCl. These proteins were loaded onto a DF4 anity column which was constructed as follow: the two complementary 58-mer DF4 oligonucleotides (40 mg) were annealed and ligated as described by Larson and Verdine (1992) using the BamHI/BglII cohesive ends; these double-stranded oligonucleotides were coupled on a Hi-trap NHS activated column (1 ml) according to the manufacturer's specifications (Pharmacia). The proteins were passaged twofold onto the column, then the column was washed with 50 ± 100 column volumes and the bound proteins eluted using KCl gradient (0.05 to 1 M) (¯ow rate 1 ml/min). Fractions of 1 ml were collected and stored at 48C. Silver staining of proteins (2 or 10 ml of the fraction) following electrophoresis (SDS ± PAGE) was performed according to Nesterenko et al. (1994) . For sequencing, the p110 containing fractions were concentrated using centriprep-30 concentrator (Amicon) (cut o 30 000). The concentrated material was electrophoresed through a 10% SDS-polyacrylamide gel. The gel was stained using Amidoblack (Aldrich) (0.003% P/V in 45% V/V methanol, 10% V/V acetic acid, 45% H 2 O) and the coloured band was cut o for sequencing analysis (performed by J D'Alayer, laboratory of microsequencing of proteins Institut Pasteur Paris).
Cell culture and transfection
QNR prepared from 8-day-old embryos were seeded at one neuroretina per 35-mm dish in DMEM 10% FCS, 24 h prior transfection. RPE prepared from 8-day-old quail embryos and QEC were seeded at 1.5610 5 cells per 35-mm-diameter dishes in the same conditions. Transfections were performed by the calcium phosphate method or using the lipofectamine reagent (GIBCO ± BRL). Cells were transfected with 10 mg of CAT constructs. Each experiment was performed in duplicate using two dierent DNA preparations without or with 0.5 mg of plasmid SV-Luc, as an internal control of transfection eciency. As transfection eciencies were very similar for all constructs, the results obtained with or without internal control were identical. For the experiments performed using PARP inhibitor aminobenzamide (3AB)(Sigma and Aldrich, dissolved in DMSO to give a stock solution 1 M), the cells were pre-incubated for 12 h prior transfection in culture medium supplemented by 10 mM of 3AB or DMSO as control. This inhibitor was added to the culture medium, after transfection. For the experiments performed using PARP inhibitor 6.5 Hphenantridinone (6.5 Hphe) the cells were supplemented in the culture medium by 100 mM of 6.5 Hphe dissolved in DMSO after transfection (Weltin et al., 1997) . MC29-infected RPE cells were obtained as previously described (Plaza et al., 1995b) and the PARP inhibitor 3AB (10 mM), was added to the culture after infection by MC29.
Luciferase and CAT assays
Forty-eight hours after transfection the cells were harvested and lysed in the reporter lysis buer (Promega). 1/10
e of the extract was tested for luciferase activity and CAT assays were performed on the remaining cell extracts as described previously (Plaza et al., 1995a) .
poly ADP-ribosyltransferase assay on nuclear extracts
The ADP-ribosyltransferase activity was determined by incubating the crude nuclear extracts (60 mg) or the puri®ed proteins (20 ml) for 3 h at 308C in the reaction mixture: 250 mM potassium phosphate buer (pH 7.4), 5 mM MgCl 2 , 20 mM dithiothreitol, 100 mM ATP and [adenylate-a-32 P]NAD (NEN) in absence or in presence of the PARP inhibitor 3AB. After reaction, the samples were analysed by SDS ± PAGE.
RNA extraction and RNase protection analysis
Total RNA was extracted by the RNAzol method (Chomczynski and Sacchi, 1987) . A 424 bp EcoRI ± HincII fragment corresponding to the 5' part of the MC29-QNR2 cDNA and cloned into the pGEM4 vector described in Dozier et al. (1993) was used to synthesise the antisense RNA probe in the presence of [a 32 P]CTP under conditions provided by the riboprobe system (Promega). RNase protections were performed with 20 mg of RNA as described previously and the protected fragments were separated on a 6% sequencing gel.
Northern blot analysis
Total RNA was extracted from cell cultures by using the guanidinium thiocyanate-caesium chloride method. RNA were denatured at 688C in a formamide-formaldehyde mixture, separated by electrophoresis in a 1% agarose-2.2 M formaldehyde gel, transferred to nitrocellulose ®lter in 206SSC (standard saline citrate) and hybridized to DNA probes labelled by random priming. Quail PARP probe was a cDNA fragment isolated from a E8 neuroretina cDNA library. The 28S oligonucleotide was used to normalise the amount of RNA (Barbu and Dautry, 1989) .
Bandshift experiments
Labelled double-stranded oligonucleotides were prepared as described previously (Plaza et al., 1995a) . Labelled oligonucleotide (1 ng) was incubated on ice for 1 h with 1 mg of nuclear extracts in the presence of 5 mg of poly(dIdC) in a ®nal volume of 16 ml of 0.56DB buer. Antibodies were incubated with the nuclear extracts for 30 min at 308C before or after adding the probe. Anti PARP antibodies were obtained from Aparptosis (G Poirier) and from a generous gift of G deMurcia. For PARP depletion experiments, antibodies were ®rst incubated with protein A sepharose for 30 min at room temperature, and nuclear extracts were further incubated with the beads for 1 h at room temperature and centrifuged. Nuclear extracts were depleted using non immune serum as control. The DNA-protein complexes were analysed by electrophoresis on a 6% polyacrylamide gel in 0.256Tris-borate-EDTA at room temperature for 2 h at 180 V, and the gel was dried for autoradiography.
Southwestern and Western blot analysis
Southwestern (DNA-protein) blotting was performed with 100 mg of E8 QNR, QEC or RPE crude nuclear extracts and the double-stranded DF4 oligonucleotide as a probe, as described previously (Plaza et al., 1995a) . Western blot analysis were performed essentially as described previously (CarrieÁ re et al., 1993) using the same membrane. Bound antiPARP antibodies were revealed using the ECL kit (Amersham).
DNaseI footprinting
The footprinting probes were prepared as already described (Plaza et al., 1995a) . End-labelled DNA fragment (5 ng) was incubated on ice for 1 h with 100 mg of nuclear proteins or using 10 ml of the puri®ed proteins in the presence of 5 mg of poly(dI-dC) in 50 ml of 0.56DB buer supplemented with 5 mM MgCl 2 and 2.5 mM CaCl 2 . After incubation, the mixture was treated as described previously (Plaza et al., 1995a) .
